McKnight's January 26, 2022
Danielle Brown

Labor shortages and rising costs aren’t expected to limit healthcare deal volume in 2022, according to a new survey of more than 300 industry executives.

The survey findings, published this week by advisory firm KPMG, showed that 70% of healthcare and life sciences executives expect increased M&A activity in 2022 — with more than half of them saying they plan to do at least 10% more deals in 2021.

“While economic headwinds could always change the course of investor sentiment, it still looks like the strong momentum for deal activity we saw in 2021 will continue throughout all or most of 2022,”

Long-term care executives also expect 2022 to be a very busy time for deal-making within the industry....

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Mergers & Acquisitions / JV, Pharma / Biotech, Provider, Survey / Study, Trends
Private equity pushes wave of healthcare bankruptcies
IBM to expand cloud offering with $6.4bn HashiCorp deal
Considering a merger? Ensure it’s right for you
IBM to acquire HashiCorp in $6.4 billion deal, reports another revenue miss
All Gas No Brakes - The FTC, DOJ, and HHS Unveil Online Reporting Portal as Latest Effort to Combat Unfair and Anticompetitive Health Care Practices

Share This Article